Pieris Pharmaceuticals to Present at H.C. Wainwright 24th Annual Global Investment Conference

Rhea-AI Summary

Pieris Pharmaceuticals (NASDAQ:PIRS), a clinical-stage biotech firm, will present at the H.C. Wainwright 24th Annual Global Investment Conference on September 14, 2022, at 12:30 PM EDT. The presentation will highlight its proprietary Anticalin technology for treating respiratory diseases and cancer. A webcast will be available here. The company focuses on developing inhalable Anticalin proteins and locally-activated bispecifics for improved clinical outcomes. For more details, visit www.pieris.com.

BOSTON, MA / ACCESSWIRE / September 8, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announced that management is scheduled to present at the H.C. Wainwright 24th Annual Global Investment Conference on Wednesday, September 14, 2022 at 12:30 PM EDT. A webcast of the company's presentation will be available at this link.

About Pieris Pharmaceuticals:

Pieris is a clinical-stage biotechnology company that combines leading protein engineering capabilities and deep understanding into molecular drivers of disease to develop medicines that drive local biology to produce superior clinical outcomes for patients. Our pipeline includes inhalable Anticalin proteins to treat respiratory diseases and locally-activated bispecifics for immuno-oncology. Proprietary to Pieris, Anticalin proteins are a novel class of therapeutics validated in the clinic and by respiratory and immuno-oncology focused partnerships with leading pharmaceutical companies. For more information, visit www.pieris.com.

Investor Relations Contact:

Pieris Pharmaceuticals, Inc.
Maria Kelman
Executive Director, Investor Relations
+1 857 362 9635
kelman@pieris.com

SOURCE: Pieris Pharmaceuticals, Inc.

View source version on accesswire.com:
https://www.accesswire.com/715200/Pieris-Pharmaceuticals-to-Present-at-HC-Wainwright-24th-Annual-Global-Investment-Conference

FAQ

What is the date and time of Pieris Pharmaceuticals' presentation at the H.C. Wainwright conference?

Pieris Pharmaceuticals will present on September 14, 2022, at 12:30 PM EDT.

Where can I watch the Pieris Pharmaceuticals presentation webcast?

The webcast of Pieris Pharmaceuticals' presentation will be available at this link.

What technology does Pieris Pharmaceuticals use for its therapeutics?

Pieris Pharmaceuticals utilizes its proprietary Anticalin technology platform for developing biotherapeutics.

What type of diseases does Pieris Pharmaceuticals target with its treatments?

Pieris Pharmaceuticals focuses on respiratory diseases and cancer.

What is the primary goal of Pieris Pharmaceuticals' development efforts?

The primary goal is to achieve superior clinical outcomes through innovative therapeutics.